전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-4 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved1,016 programs
CGTLimited DatastaleCG Oncology, Inc.Phase 2

oncolytic adenovirus expressing GMCSF (oncolytic adenovirus expressing GMCSF)

Bladder Cancer; High Grade · Bladder Cancer

#BladderCancer#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 2Status Discontinued
CGTLimited DatastaleKevin FlaniganPhase 2

rAAVrh74.MCK.GALGT2 (rAAVrh74.MCK.GALGT2)

Duchenne Muscular Dystrophy · Duchenne Muscular Dystrophy

#DuchenneMuscularDystrophy#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 2Status Active
CGTLimited DatastaleCancer Research UKPhase 1

1RG-CART (1RG-CART)

Relapsed or Refractory Neuroblastoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
ADCLimited DatastaleThe Netherlands Cancer InstitutePhase 2

89Zr-Patritumab deruxtecan (89Zr-Patritumab deruxtecan)

Non-Small Cell Lung Carcinoma; Advanced Non-Small Cell Squamous Lung Cancer · EGFR

#EGFR#ADC#Phase2#antibody-drug-conjugate#Non-SmallCellLungCarcinoma+2
Trials 1Status Recruiting
CGTAAVLimited DatastaleUniversity of OxfordPhase 2

AAV-mediated REP1 gene replacement (AAV-mediated REP1 gene replacement)

Choroideremia · Choroideremia

#Choroideremia#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTAAVLimited DatastaleMeiraGTx, LLCPhase 2

AAV2-hAQP1 (AAV2-hAQP1)

Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Paroti… · Grade 2 and 3 Late Xerostomia Caused by

#Grade2and3LateXerostomiaCausedby#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTAAVLimited DatastaleMeiraGTx, LLCPhase 2

AAV2-hAQP1 Concentration 1 (AAV2-hAQP1 Concentration 1)

Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Paroti… · Grade 2 and 3 Late Xerostomia Caused by

#Grade2and3LateXerostomiaCausedby#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTAAVLimited DatastaleMeiraGTx, LLCPhase 2

AAV2-hAQP1 Concentration 2 (AAV2-hAQP1 Concentration 2)

Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Paroti… · Grade 2 and 3 Late Xerostomia Caused by

#Grade2and3LateXerostomiaCausedby#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTAAVLimited DatastaleMeiraGTx, LLCPhase 2

AAV2-hAQP1 Concentration 3 (AAV2-hAQP1 Concentration 3)

Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Paroti… · Grade 2 and 3 Late Xerostomia Caused by

#Grade2and3LateXerostomiaCausedby#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTAAVLimited DatastaleMeiraGTx, LLCPhase 2

AAV2-hAQP1 Concentration 4 (AAV2-hAQP1 Concentration 4)

Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Paroti… · Grade 2 and 3 Late Xerostomia Caused by

#Grade2and3LateXerostomiaCausedby#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTAAVLimited DatastaleGenzyme, a Sanofi CompanyPhase 1

AAV2-sFLT01 (AAV2-sFLT01)

Macular Degeneration; Age-Related Maculopathies · Macular Degeneration

#MacularDegeneration#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTAAVLimited DatastaleCelosia Therapeutics Pty LtdPhase 1

AAV9 Gene therapy (AAV9 Gene therapy)

ALS (Amyotrophic Lateral Sclerosis) · ALS (Amyotrophic Lateral Sclerosis)

#ALSAmyotrophicLateralSclerosis#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTAAVLimited DatastaleUnlimited Biotechnology LLCPhase 2

AAV9-Follistatin gene therapy (AAV9-Follistatin gene therapy)

Age-related Muscle Decline · Age-related Muscle Decline

#Age-relatedMuscleDecline#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleAkouos, Inc.Phase 2

AAVAnc80-hOTOF via Akouos Delivery Device (AAVAnc80-hOTOF via Akouos Delivery Device)

Sensorineural Hearing Loss, Bilateral · Sensorineural Hearing Loss, Bilateral

#SensorineuralHearingLossBilatera#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleAkouos, Inc.Phase 2

AAVAnc80-hOTOF via Akouos Delivery Device and Precision Delivery Mechanism (AAVAnc80-hOTOF via Akouos Delivery Device and Precision Delivery Mechanism)

Sensorineural Hearing Loss, Bilateral · Sensorineural Hearing Loss, Bilateral

#SensorineuralHearingLossBilatera#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleJanssen Research & Development,…Phase 1

AAVCAGsCD59 (AAVCAGsCD59)

Dry Age-related Macular Degeneration · Dry Age-related Macular Degeneration

#DryAge-relatedMacularDegeneratio#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTAAVLimited DatastaleWeill Medical College of Cornel…Phase 2

AAVrh.10CUCLN2 (AAVrh.10CUCLN2)

Late Infantile Neuronal Ceroid Lipofuscinosis; Batten Disease · Late Infantile Neuronal Ceroid Lipofusci

#LateInfantileNeuronalCeroidLipof#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTAAVLimited DatastaleWeill Medical College of Cornel…Phase 1

AAVrh.10CUhCLN2 vector 2.85x10^11 genome copies (AAVrh.10CUhCLN2 vector 2.85x10^11 genome copies)

Batten Disease; Late-Infantile Neuronal Ceroid Lipofuscinosis · Batten Disease

#BattenDisease#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTAAVLimited DatastaleWeill Medical College of Cornel…Phase 1

AAVrh.10CUhCLN2 vector 9.0x10^11 genome copies (AAVrh.10CUhCLN2 vector 9.0x10^11 genome copies)

Batten Disease; Late-Infantile Neuronal Ceroid Lipofuscinosis · Batten Disease

#BattenDisease#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleInge Marie SvanePhase 1

ADP-TILIL7 (ADP-TILIL7)

Melanoma Stage III; Melanoma Stage IV · Melanoma Stage III

#MelanomaStageIII#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting

19 / 51 pages

← PreviousNext →